Oxford Asset Management’s Adicet Bio ACET Stock Holding History

Oxford Asset Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-204	Closed	-$34K	–	218
2019 Q4	$34K	Sell	204 -84	-29%	-$42.5K	﹤0.01%	1680
2019 Q3	$285K	Buy	288 +173	+150%	+$193K	0.01%	1477
2019 Q2	$132K	Buy	+115	New	+$104K	﹤0.01%	1597
2019 Q1	–	Sell	-205	Closed	-$198K	–	1621
2018 Q4	$198K	Buy	+205	New	+$270K	0.01%	1537

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ruffer LLP London, United Kingdom $2.44B AUM 44.75% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Oxford Asset Management's ACET Position: Q1 2020 in Review

Oxford Asset Management sold out of Adicet Bio (ACET) in Q1 2020, closing a stake of 204 shares — an estimated $34K sold.

Oxford Asset Management first reported a position in ACET in Q4 2018 and held it in 4 quarters. The position peaked at $285K in Q3 2019. 51 funds tracked by Wall St. Rank hold ACET as of Q1 2020.

Oxford Asset Management reported no remaining Adicet Bio position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 204 Adicet Bio shares in Q1 2020, an estimated $34K.
Oxford Asset Management first reported a position in Adicet Bio in Q4 2018 and held it in 4 quarters.
Oxford Asset Management's Adicet Bio position peaked at $285K in Q3 2019.
51 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.